202 related articles for article (PubMed ID: 35566609)
1.
Raphael A; Dudnik E; Hershkovitz D; Jain S; Olsen S; Soussan-Gutman L; Ben-Shitrit T; Dvir A; Nechushtan H; Peled N; Onn A; Agbarya A; On Behalf Of The Israel Lung Cancer Group
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566609
[TBL] [Abstract][Full Text] [Related]
2. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
3. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report.
Enrico D; Lacroix L; Chen J; Rouleau E; Scoazec JY; Loriot Y; Tselikas L; Jovelet C; Planchard D; Gazzah A; Mezquita L; Ngo-Camus M; Michiels S; Massard C; Recondo G; Facchinetti F; Remon J; Soria JC; André F; Vassal G; Friboulet L; Besse B
JTO Clin Res Rep; 2020 Jun; 1(2):100023. PubMed ID: 34589930
[TBL] [Abstract][Full Text] [Related]
5. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
Zhu VW; Klempner SJ; Ou SI
Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
[TBL] [Abstract][Full Text] [Related]
6. Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.
Zhou Z; Liu Z; Ou Q; Wu X; Wang X; Shao Y; Liu H; Yang Y
Cancer Biol Med; 2021 Mar; 18(2):490-501. PubMed ID: 33710807
[TBL] [Abstract][Full Text] [Related]
7. Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.
Xu H; Shen J; Xiang J; Li H; Li B; Zhang T; Zhang L; Mao X; Jian H; Shu Y
Cancer Manag Res; 2019; 11():6343-6351. PubMed ID: 31372039
[No Abstract] [Full Text] [Related]
8. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
9. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.
Schrock AB; Zhu VW; Hsieh WS; Madison R; Creelan B; Silberberg J; Costin D; Bharne A; Bonta I; Bosemani T; Nikolinakos P; Ross JS; Miller VA; Ali SM; Klempner SJ; Ou SI
J Thorac Oncol; 2018 Sep; 13(9):1312-1323. PubMed ID: 29883838
[TBL] [Abstract][Full Text] [Related]
10. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
Ware KE; Marshall ME; Heasley LR; Marek L; Hinz TK; Hercule P; Helfrich BA; Doebele RC; Heasley LE
PLoS One; 2010 Nov; 5(11):e14117. PubMed ID: 21152424
[TBL] [Abstract][Full Text] [Related]
11. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
[TBL] [Abstract][Full Text] [Related]
12. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
13. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.
Ware KE; Hinz TK; Kleczko E; Singleton KR; Marek LA; Helfrich BA; Cummings CT; Graham DK; Astling D; Tan AC; Heasley LE
Oncogenesis; 2013 Mar; 2(3):e39. PubMed ID: 23552882
[TBL] [Abstract][Full Text] [Related]
14. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
15. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
Xia H; Xue X; Ding H; Ou Q; Wu X; Nagasaka M; Shao YW; Hu X; Ou SI
Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448
[TBL] [Abstract][Full Text] [Related]
16. Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma.
Balasubramanian B; Yacqub-Usman K; Venkatraman S; Myint KZ; Juengsamarn J; Sarkhampee P; Lertsawatvicha N; Sripa J; Kuakpaetoon T; Suriyonplengsaeng C; Wongprasert K; Grabowska AM; Bates DO; Janvilisri T; Tohtong R
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173994
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
18. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
19. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
[TBL] [Abstract][Full Text] [Related]
20. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]